Plasma cell neoplasm

Researchers are testing a new type of immune cell therapy called CS1-targeted CAR-T in adults with multiple myeloma that has come back or stopped responding to treatment. The study enrolls about 10 participants who have already received several lines of therapy. Doctors collect a…

Researchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…

This early-stage trial is testing whether immune cells from a donor, specially trained to attack HIV, can safely reduce the hidden HIV reservoir in people who have had a bone marrow transplant. Participants are adults with HIV who are on antiretroviral therapy and have already re…

This trial tests a new, lower-intensity combination of chemotherapy and radiation before a donor stem cell transplant for people with high-risk blood cancers or aplastic anemia. The goal is to see if this approach is safe enough to allow the donor cells to take hold and cure the …

This early-phase trial is testing a new gene therapy called ESO-T01 for people with relapsed or refractory multiple myeloma, a blood cancer that has stopped responding to standard treatments. ESO-T01 is given as an injection and works by instructing the body's own cells to become…

This early-phase trial tests whether a vaccine made from a protein called survivin can safely boost the immune system to fight multiple myeloma. The study involves 18 patients who have already responded to initial treatment and are taking lenalidomide as maintenance therapy. The …

This study tests a new COVID-19 vaccine (GEO-CM04S1) in 63 adults with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. The goal is to see if this vaccine triggers a stronger immune response than standard mRNA vaccines, potentially offe…

This study tests whether extra COVID-19 vaccine doses are safe and work well for people with weakened immune systems, such as those with HIV, organ transplants, or blood cancers. Around 960 participants will receive different booster schedules to see which one boosts their protec…

This study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs…

This phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…

This study tests a drug called crizotinib in people whose cancer has a specific genetic change called ROS1 translocation. The drug blocks a protein that may help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. Only 4 people took part,…

This early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…

This early-phase study tests a new treatment for multiple myeloma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in the lab to recognize and attack cancer cells carrying a protein called CD138. …

This phase 3 trial tests whether iberdomide is better than lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays cancer progression longer. The st…

This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…

This phase 3 study tests whether adding daratumumab to the standard drug lenalidomide as maintenance therapy after a stem cell transplant can better control multiple myeloma. About 1,100 participants will be randomly assigned to receive either lenalidomide alone or lenalidomide p…

This early-phase trial tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have come back or not responded to standard treatments. The immune cells are modified in the lab to r…

Researchers are testing whether daratumumab and lenalidomide can treat newly diagnosed multiple myeloma without adding steroids. The trial enrolls patients who are not candidates for high-dose chemotherapy and have not received prior treatment. The goal is to see how often infusi…

This phase 2 trial tests a combination of four drugs—isatuximab, carfilzomib, pomalidomide, and dexamethasone—in 30 patients with multiple myeloma that has relapsed or become resistant to treatment. The goal is to see how many patients respond to this regimen. All participants ha…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

Researchers are testing whether adding selinexor to carfilzomib, daratumumab, and dexamethasone helps patients with high-risk multiple myeloma that has returned or stopped responding to treatment. Participants must have received one to three prior lines of therapy and be sensitiv…

This study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…

This phase 2 trial is testing whether adding the drug daratumumab to a standard treatment plan helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. The study involves 50 participants and uses a combination of daratumumab, carfilzomib,…

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This early-stage study is testing whether a combination of two drugs—elranatamab (given as a shot) and iberdomide (taken as a pill)—is safe and tolerable for people with multiple myeloma that has returned or stopped responding to prior treatments. The trial will enroll about 87 p…

This phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…

This phase 2 trial compares daratumumab and lenalidomide as maintenance therapy for people with newly diagnosed multiple myeloma who have responded well to initial treatment. The main goal is to see which drug provides better health-related quality of life, measured through quest…

Researchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

Researchers are testing whether adding the antibody drug isatuximab to dexamethasone before and after an autologous stem cell transplant helps patients with relapsed multiple myeloma. About 50 adults who already had a transplant and later relapsed will receive three cycles of isa…

This early-phase trial tests a new approach for high-risk multiple myeloma: a radioactive antibody that targets cancer cells, followed by a donor stem cell transplant. The antibody delivers radiation directly to myeloma cells, while chemotherapy and low-dose radiation help prepar…

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This early-phase trial tests whether combining talquetamab (a targeted antibody drug) with radiation therapy can safely treat multiple myeloma that has spread to organs or soft tissues. About 20 adults with this hard-to-treat condition will receive radiation to the tumor site plu…

Researchers are testing whether a combination of daratumumab, pomalidomide and dexamethasone can help people whose multiple myeloma has come back and carries a genetic change called del(17p). This change, found in about 10% of patients at diagnosis, makes the cancer harder to tre…

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This phase 2 trial tests whether the drug iberdomide, taken after CAR-T therapy, can keep multiple myeloma under control longer than just monitoring. About 78 participants will be randomly assigned to receive iberdomide or standard monitoring. The study is currently suspended.

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This phase II trial tests the drug afatinib in 40 people with advanced cancers (like solid tumors or lymphoma) that have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer growth. The study aims to see if the …

This study tests a drug called daratumumab in 40 people with a rare kidney condition called PGNMID, where abnormal proteins damage the kidneys. Participants receive weekly injections for 8 weeks, then every two weeks for another 8 weeks. The goal is to see if the drug can reduce …

This phase III trial tests whether a smartphone app called Quit2Heal can help cancer patients stop smoking better than the standard QuitGuide app. The study involves 427 adults with cancer who smoke and are interested in quitting. Participants use one of the two apps to get suppo…

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study tests whether adding the drug iberdomide to a standard treatment (belantamab mafodotin plus dexamethasone) is safe and works better for multiple myeloma that has relapsed or become resistant. About 88 participants will receive either the new combo or the standard combo…

This phase II trial tests whether adding the drug axatilimab to standard care can prevent graft-versus-host disease (GVHD) in 72 blood cancer patients receiving a stem cell transplant. GVHD occurs when donor cells attack the patient's body, causing serious symptoms. Axatilimab is…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This study tests if a shot under the skin works as well as an IV infusion for a multiple myeloma drug combination. About 531 adults with relapsed or hard-to-treat myeloma are taking part. The goal is to see if the shot gives similar cancer-fighting results and is easier for patie…

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This phase 2 trial tests whether the drug elranatamab can help people with high-risk smoldering multiple myeloma, a condition where abnormal plasma cells are present but have not yet caused active disease. About 50 adults with this condition will receive elranatamab as a subcutan…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This trial tests whether adding a protein called CYT107 to the standard treatment for multiple myeloma helps the immune system recover faster after a stem cell transplant. The standard treatment includes a chemotherapy drug called melphalan and the transplant itself. Researchers …

This phase 3 trial tests whether a one-time infusion of cilta-cel, a CAR-T cell therapy, works better than standard drug combinations (PVd or DPd) for people with multiple myeloma that has come back and no longer responds to lenalidomide. About 419 participants will be randomly a…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This study is testing a new treatment called JNJ-68284528, a CAR-T cell therapy, for people with multiple myeloma. The goal is to see if it can reduce cancer cells to undetectable levels (called minimal residual disease negative). About 210 participants who have already tried oth…

This early-stage study tests a new drug called teclistamab in people with multiple myeloma that has returned or stopped responding to other treatments. The main goal is to find a safe dose and check for side effects. About 300 participants will receive the drug to see how well it…

This early-phase study tests the safety of talquetamab combined with other cancer drugs in 166 people with multiple myeloma, a type of blood cancer. The goal is to find safe doses and check for side effects. Participants must have measurable disease and meet specific lab criteria…

This study tests whether a new two-drug combination (teclistamab plus daratumumab) works better than standard three-drug combos for people whose multiple myeloma has returned or stopped responding to treatment. About 587 adults with measurable disease will be randomly assigned to…

This early-phase study is testing a combination of two treatments—cilta-cel (a cell therapy) and talquetamab (a drug)—in 11 people with high-risk multiple myeloma that has not responded to prior therapies. The main goal is to check safety and side effects. Researchers will also l…

This early-phase study tests a new drug, JNJ-87562761, in 17 people with multiple myeloma whose cancer returned or didn't respond to prior treatments. The main goals are to find a safe dose and check for side effects. Participants must have measurable disease and have tried certa…

This early-stage trial tests combinations of the drug daratumumab with two newer bispecific antibodies (talquetamab and teclistamab), with or without pomalidomide, in 290 people with multiple myeloma. The main goal is to find safe doses and understand side effects. Participants m…

This early-stage study tests an experimental drug called cevostamab in about 20 Chinese adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tum…

This early-stage study tests a new drug called teclistamab combined with other cancer treatments for people with multiple myeloma, a type of blood cancer. The main goal is to check safety and find the best doses. About 140 participants who have already tried other treatments will…

This study compares two versions of the drug teclistamab—one made with the current process and one with a new process—in 108 people with multiple myeloma that has come back or not responded to treatment. The main goal is to see if the body absorbs and handles both versions the sa…

This study is for people newly diagnosed with a standard-risk form of multiple myeloma, a blood cancer. Researchers want to see if giving a sequence of advanced cell therapies (Cilta-cel, Tal-D, Tec-D) after initial chemotherapy can lead to a very deep and lasting remission, poss…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This study tests the safety of teclistamab, a drug given as a shot, in 75 Indian adults with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see how safe it is in routine practice. Participants must have tried specific prior…

This study tested two different doses of dexamethasone combined with lenalidomide in 452 people newly diagnosed with multiple myeloma. The goal was to see which dose worked better at shrinking tumors. If the first treatment didn't work, patients could switch to a thalidomide-base…

This study compares two drug combinations—melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR)—in 306 newly diagnosed multiple myeloma patients who cannot have high-dose therapy. The goal is to see which combination better delays cance…

This study tests whether adding the experimental drug talquetamab to standard treatments (daratumumab and pomalidomide) helps people with multiple myeloma that has returned or stopped responding to prior therapy. About 864 adults will receive either the new combination or the usu…

This early-stage study tests whether combining two types of immune-boosting drugs (bispecific antibodies and a checkpoint inhibitor) is safe for people with multiple myeloma that has come back or stopped responding to treatment. About 74 participants will receive either talquetam…

This study provides ongoing access to daratumumab-based treatment for 500 adults with multiple myeloma who are already benefiting from it in earlier Janssen trials. The main goal is to monitor long-term safety, including serious side effects and infections. Participants continue …

This phase 3 study compares two new drug combinations (talquetamab plus pomalidomide or talquetamab plus teclistamab) against standard treatments for multiple myeloma, a blood cancer. About 795 participants will be randomly assigned to one of the groups. The goal is to see which …

This phase 3 trial compares a new CAR-T cell therapy (cilta-cel) plus standard drugs against standard drugs alone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 743 participants will receive either the CAR-T combination or standard …

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or stopped responding. About 380 participants will receive either etentamig or a standard therapy chosen by their doctor. The goal is to see if etentamig ca…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This phase 3 trial studies whether taking lenalidomide (Revlimid) after an autologous stem cell transplant can delay the return of multiple myeloma compared to a placebo. About 460 patients with active myeloma who had a stem cell transplant are involved. The main goal is to see h…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This phase 2 trial tests whether combining belantamab mafodotin (a targeted antibody-drug conjugate) with lenalidomide can eliminate minimal residual disease in multiple myeloma patients who still have detectable cancer after a stem cell transplant. The study enrolls 4 adults who…

This early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…

This study tests a combination of four drugs—carfilzomib, lenalidomide, vorinostat, and dexamethasone—in people with multiple myeloma that has relapsed or not responded to prior treatment. The goal is to find a safe dose and see if the combination helps control the cancer. Sevent…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This early-stage trial tests two new drug combinations for people with multiple myeloma that has returned or stopped responding to treatment. One group gets elranatamab (an immune-boosting shot) plus carfilzomib and dexamethasone; the other gets elranatamab plus maplirpacept. The…

This study tests a combination of four drugs—daratumumab, carfilzomib, lenalidomide, and dexamethasone—in 39 adults newly diagnosed with multiple myeloma, a blood cancer. The goal is to see how many patients achieve a complete or stringent complete response after initial treatmen…

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This trial is testing whether a combination of three drugs—ixazomib, pomalidomide, and dexamethasone—can help people with multiple myeloma that has relapsed or become resistant after prior treatments like daratumumab, lenalidomide, and bortezomib. The study will measure how long …

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…

This early-stage trial is testing a new drug called SG301 in about 61 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose to use in future studies. Researche…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This study tests a specific timing of chemotherapy drugs (busulfan and fludarabine) before a donor stem cell transplant, followed by cyclophosphamide after the transplant, to treat high-risk blood cancers like leukemia and lymphoma. The goal is to reduce the chance of the transpl…

This study tests a drug called cevostamab in 90 people with multiple myeloma that has returned or not responded to prior treatments, including BCMA-targeted therapies. Participants receive cevostamab by IV every 3 weeks. The goal is to see if the drug can shrink tumors and how sa…

This early-stage trial tests whether specially trained immune cells can safely target and attack multiple myeloma, as well as its early forms MGUS and smoldering myeloma. Up to 36 participants will receive two infusions of their own T cells that have been engineered to recognize …

This study looks at whether it is safe to remove one immune-suppressing drug, mycophenolate mofetil (MMF), from the standard treatment plan after a stem cell transplant for blood cancers. Sixty adults aged 18 to 75 will receive the transplant without MMF and be monitored for up t…

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This study offers continued treatment with isatuximab (a targeted antibody) to adults with multiple myeloma who were already benefiting from it in earlier trials. About 70 participants will receive the drug, possibly combined with other medications, to monitor long-term safety. T…

This study tests a drug called teclistamab in people with multiple myeloma that has come back or stopped responding to treatment. The drug is a special antibody that helps the body's immune cells find and attack cancer cells. About 194 participants will receive the drug to see ho…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This study tests a new treatment called anitocabtagene autoleucel (a type of cell therapy) against standard treatments for people with multiple myeloma that has returned or not responded to 1-3 prior therapies. About 450 participants will be randomly assigned to receive either th…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This phase 2 trial tests whether a combination of daratumumab, lenalidomide, and dexamethasone, followed by a stronger regimen if needed, can make multiple myeloma undetectable at a deep level (MRD-negative) in newly diagnosed patients. The treatment plan adapts based on each per…

This phase 1 trial tests whether a special imaging tracer can track CAR-T cells in people with extramedullary myeloma, a type of myeloma that forms tumors outside the bone marrow. Participants receive cilta-cel, a CAR-T therapy targeting the BCMA protein on myeloma cells, along w…

This study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled f…

This phase 2 trial tests whether adding isatuximab to standard stem cell transplant procedures can help the immune system better fight multiple myeloma and certain lymphomas. Participants are randomly assigned to receive either standard transplant care alone or isatuximab plus st…

This phase 2 trial tests whether a combination of isatuximab, lenalidomide, and dexamethasone can eliminate minimal residual disease (MRD) in multiple myeloma patients who still have detectable cancer cells after a stem cell transplant. About 30 adults will receive the drug combo…

This phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from get…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This phase 2 trial tests whether adding the drug daratumumab to a standard chemotherapy combination (bortezomib, cyclophosphamide, and dexamethasone) works better than the current standard (bortezomib, thalidomide, and dexamethasone) for newly diagnosed multiple myeloma patients …

This phase 3 trial tests whether adding the targeted antibody isatuximab to a standard three-drug regimen (carfilzomib, lenalidomide, dexamethasone) can achieve deeper remissions in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Particip…

This phase 2 trial is testing the drug iberdomide (CC220) as a long-term maintenance therapy for people with newly diagnosed multiple myeloma who have already had a stem cell transplant. The goal is to see if taking iberdomide continuously can improve the depth of response and he…

This study looks at whether people with plasma cell disorders can safely recover from an autologous stem cell transplant at home instead of in the hospital. Researchers want to see if home recovery is practical, reduces infections, and keeps patients satisfied. About 91 adults ag…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This phase 1 trial tests a new approach for people with high-risk multiple myeloma who are already responding to their first or second line of therapy. The study uses a patient's own immune cells, engineered to recognize and attack the cancer (CART-BCMA), sometimes combined with …

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This phase II trial is testing the drug palbociclib in 40 patients whose advanced cancers have extra copies of the CCND1, 2, or 3 genes. Palbociclib blocks proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. The study …

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This phase 2 trial tests whether the drug lenalidomide, taken as maintenance therapy, can delay the return of multiple myeloma in patients who have already responded to initial treatment. Participants take lenalidomide daily and are monitored for how long they remain free of dise…

This early-stage trial tests a new drug called talquetamab in 279 people with multiple myeloma that has come back or stopped responding to other treatments. Talquetamab is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check sa…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This phase 1 trial tests a new approach for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The study uses two different CAR T cell therapies—one targeting a protein called GPRC5D and another targeting BCMA—given together …

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This phase 2 trial tests whether a combination of four drugs—daratumumab, bortezomib, lenalidomide, and dexamethasone—can stop high-risk smoldering multiple myeloma from progressing to active multiple myeloma. Participants must be 18 or older and meet specific high-risk criteria.…

This phase 3 trial tests a new drug, belantamab mafodotin, against a standard treatment (pomalidomide plus dexamethasone) in 325 people with multiple myeloma that has returned or stopped responding to prior therapy. The main goal is to see if the new drug delays cancer progressio…

This study tests a new treatment for a rare and aggressive blood cancer called primary plasma cell leukemia. The approach combines chemotherapy, a stem cell transplant, and two infusions of specially engineered immune cells (CAR-T cells) that target the cancer. The goal is to see…

This study tests a drug called belantamab mafodotin in people with multiple myeloma that has come back or stopped responding to treatment, and who also have kidney problems—from mild impairment to end-stage disease requiring dialysis. The drug is an antibody-drug conjugate that t…

This early-phase trial tests a new immune cell therapy called CS1-CAR T cells for people with multiple myeloma that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, engineering them in a lab to recognize and attack myeloma cel…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This study was designed to test a new drug called linvoseltamab combined with standard chemotherapy drugs (bortezomib and lenalidomide) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if this combination, with or wi…

This phase 2 trial is testing a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and daratumumab) given before and after a stem cell transplant for people with multiple myeloma that has come back after prior treatment. The study includes 41 participants and ai…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This study tests a combination of three oral drugs—ixazomib, iberdomide, and dexamethasone—in patients over 70 with multiple myeloma that has returned after initial treatment. The goal is to see how many patients achieve a very good partial response or better. 75 participants wil…

This study tests a drug called iberdomide as maintenance therapy for people with multiple myeloma who have had a stem cell transplant. The goal is to see if more patients can stay on treatment for at least a year without the disease getting worse. About 40 adults will take iberdo…

This phase 3 trial tests whether a new combination of drugs—belantamab mafodotin, pomalidomide, and dexamethasone—works better than a standard combo for people with multiple myeloma that has returned or not responded to treatment. The study involves 21 Japanese adults who have al…

This phase 3 study tests whether adding the targeted drug belantamab mafodotin to standard medications (pomalidomide and dexamethasone) works better than another standard combo for people with multiple myeloma that has come back or stopped responding to treatment. About 302 parti…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…

This phase II trial is testing new therapies, including the drug teclistamab, for people with multiple myeloma that has relapsed or not responded to treatment. About 300 participants will be enrolled in an adaptive platform design that allows adding new treatment arms over time. …

This phase 2 trial is testing a drug called elranatamab in 50 people with multiple myeloma that has relapsed or stopped responding after at least one prior treatment. Participants have already tried three main drug classes. The goal is to see if elranatamab can reduce the cancer …

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This early-stage study tests a new drug called HRS-3738 in people with two types of blood cancer—non-Hodgkin's lymphoma and multiple myeloma—that have returned or not improved after prior treatments. The main goals are to find a safe dose and check how well the drug works. About …

This study tests whether adding iberdomide (a new oral drug) to standard treatments can eliminate tiny amounts of myeloma cells that remain after a stem cell transplant. About 80 adults with multiple myeloma who still have detectable cancer cells after transplant will receive one…

This phase 2 trial tests a new approach for people newly diagnosed with multiple myeloma who have a high-risk genetic change (P53 abnormality). The treatment combines standard chemotherapy with a double dose of specially engineered immune cells (CAR-T cells) and a stem cell trans…

This study tests a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and isatuximab) in 50 adults newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see how many patients achieve a complete response after four trea…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This study was designed to test a new type of cell therapy (BCMA-GPRC5D CAR-T) for people with relapsed/refractory multiple myeloma, a blood cancer that had not responded to at least three prior treatments. The goal was to check the treatment's safety and early signs of effective…

This study tests an experimental drug called GR1803 in 116 people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see how well the drug shrinks or controls the cancer, and to check its safety. Participants receive the drug for up to 2 y…

This phase II trial tests a combination of eight chemotherapy drugs given in lower doses and shorter cycles to people with high-risk multiple myeloma. The goal is to prevent myeloma cells from regrowing between treatments, leading to longer remissions and better survival. The stu…

This phase 3 trial tests whether a less intense version of a standard chemotherapy regimen can reduce side effects by half while still controlling low-risk multiple myeloma in adults 65 and under. Participants receive a combination of drugs, a stem cell transplant, and three year…

This study tests whether the drug iberdomide can safely improve outcomes for people with multiple myeloma who had a less-than-ideal response after a stem cell transplant and previous maintenance therapy. Sixteen participants will take iberdomide and be monitored for disease progr…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This phase 2 trial is testing a combination of four drugs—isatuximab, carfilzomib, lenalidomide, and dexamethasone—in 246 people newly diagnosed with high-risk multiple myeloma. The goal is to see if this intensive regimen can make the cancer undetectable (MRD-negative) and keep …

This phase 2 trial tests a combination of four drugs (carfilzomib, daratumumab, lenalidomide, and dexamethasone) in 17 people with high-risk multiple myeloma. The goal is to see if the treatment can clear even tiny amounts of cancer left after initial therapy, known as minimal re…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study offers ongoing treatment with the drug CC-122 (Avadomide) to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor long-term safety and serious side effects. Par…

This study tests a new combination of three drugs—belantamab mafodotin, carfilzomib, and dexamethasone—in people whose multiple myeloma has returned and is no longer responding to lenalidomide. The trial has two parts: first, finding the safest dose, then testing that dose in up …

This phase 2 trial tests a new way of giving chemotherapy to people with high-risk multiple myeloma who have already had some treatment. Instead of high doses with long breaks, researchers give lower doses in shorter cycles to prevent cancer cells from regrowing. The goal is to i…

This phase 2 pilot study tests two new drug combinations—teclistamab plus daratumumab and talquetamab plus daratumumab—in 30 people newly diagnosed with high-risk multiple myeloma. The goal is to see if these treatments can make the cancer undetectable (MRD-negative complete remi…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This phase 2 trial is testing two drug combinations—iberdomide plus dexamethasone, with or without daratumumab—in 140 newly diagnosed multiple myeloma patients aged 65 or older who are not eligible for a stem cell transplant. The goal is to see how well these treatments control t…

This study is for people with systemic amyloidosis, a disease where abnormal proteins build up in organs. It tests the long-term safety of an experimental drug called AT-02. About 120 adults will receive the drug and be monitored for side effects and how the drug behaves in the b…

This study tests whether adding isatuximab to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who cannot have a stem cell transplant live longer without their cancer worsening. About 475 participant…

This study tests a combination of two drugs, belantamab mafodotin and nirogacestat, in people with multiple myeloma that has returned or not responded to at least three prior treatments. The goal is to find a safe dose and see how well the combination shrinks tumors. About 106 ad…

This study tests a targeted drug called belantamab mafodotin, alone or with other cancer medicines, in people with multiple myeloma that has returned or stopped responding to prior treatments. About 208 adults will take part to see if these combinations are safe and effective. Th…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This study tests a new way to give a drug called isatuximab as a quick shot under the skin, instead of a long IV drip, for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The shot is combined with three standard chemotherapy drugs. The goal is…

This study tests whether transferring stool from a healthy person into the gut of adults with blood cancers can restore good bacteria lost during chemotherapy. The goal is to reduce dangerous infections and improve quality of life. One hundred participants will be followed long-t…

This phase 2 trial is testing whether leflunomide, a drug used for arthritis, can delay the onset of multiple myeloma in 27 people with high-risk smoldering multiple myeloma. The study includes both African-American and European-American participants to see if the drug works diff…

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This study planned to test a type of immunotherapy called BCMA CAR-T cells in people with high-risk multiple myeloma who still had signs of cancer after a stem cell transplant. The goal was to see if the treatment could clear remaining cancer cells and improve outcomes. However, …

This phase II trial aimed to test the drug itacitinib in people with severe side effects from cancer immunotherapy that did not get better with steroids. The goal was to see if itacitinib could calm the overactive immune response causing these side effects. However, the study was…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This early-stage trial is testing a new therapy called P-BCMA-ALLO1 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses donor immune cells that are engineered to find and attack myeloma cells. The main goals are to check s…

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study tests a new combination of drugs (belantamab mafodotin, bortezomib, and dexamethasone) against a standard combo (daratumumab, bortezomib, and dexamethasone) in 494 people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if the…

This study tests whether a new combination of drugs—belantamab mafodotin plus bortezomib and dexamethasone—works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people in Japan with multiple myeloma that has come back or stopped responding t…

This Phase 3 trial tests whether a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people with multiple myeloma that has come back or stopped responding to t…

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 41 people with multiple myeloma that has spread outside the bones, known as extramedullary disease. The goal is to see how well the treatment works and how safe it is. P…

This early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This Phase 3 trial tests whether elranatamab, an immune-boosting drug, works better than lenalidomide at preventing multiple myeloma from returning in patients who have just had a stem cell transplant. About 854 participants will receive either elranatamab injections or lenalidom…

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…

This study aimed to see if a special type of stem cell (hAESC) could safely prevent acute graft-versus-host disease in people receiving a stem cell transplant for blood cancer. It was designed for adults at high risk of this complication. However, the study was withdrawn before a…

This study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This early-phase study tests a combination of four drugs (cyclophosphamide, pomalidomide, dexamethasone, and daratumumab) in people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and see if the combination ca…

This study is tracking 200 adults with multiple myeloma whose cancer has returned or stopped responding to treatment. They are receiving teclistamab, a drug that helps the immune system find and destroy myeloma cells. Researchers are measuring how many patients respond to the dru…

This study compares teclistamab (a newer immunotherapy) with two standard drug combinations (PVd or Kd) in about 614 adults whose multiple myeloma has come back or stopped responding after 1 to 3 prior treatments. The main goal is to see if teclistamab helps people live longer wi…

This study tests whether adding lenalidomide (Revlimid) to the standard high-dose melphalan before an autologous stem cell transplant can improve outcomes for people with relapsed multiple myeloma. In the first phase, researchers find the safest dose of lenalidomide to combine wi…

This study tests three different drug combinations containing selinexor (Xpovio) for people whose multiple myeloma has returned or stopped responding to treatment. About 18 adults will receive a combination chosen by their doctor. The goal is to see how well these treatments shri…

This early-phase trial tests whether a probiotic called CBM588 is safe and can improve outcomes in 36 patients who have received a donor stem cell transplant. The probiotic aims to increase healthy gut bacteria and reduce gut-related side effects like diarrhea and colon inflammat…

This Phase 3 trial is testing whether adding daratumumab (a targeted antibody) to standard lenalidomide treatment can help frail older adults with newly diagnosed multiple myeloma live longer without their cancer getting worse. Around 294 participants who are not candidates for h…

This study tests a new way to do stem cell transplants for 20 children with blood cancers or myelodysplasia who don't have a perfect donor match. Doctors remove certain immune cells from a parent's partially matched stem cells before transplant to help the new cells grow faster a…

This Phase 3 trial is testing whether a new combination of drugs—iberdomide, daratumumab, and dexamethasone—can better control multiple myeloma that has come back or stopped responding to treatment, compared to a standard three-drug regimen. About 939 participants who have had 1 …

This study looks at whether people with multiple myeloma who have no signs of cancer after a stem cell transplant and at least one year of maintenance therapy can safely stop taking their medication. Researchers will use advanced imaging and lab tests to detect even tiny amounts …

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This phase 3 study tests whether adding the experimental drug mezigdomide to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with relapsed or refractory multiple myeloma live longer without their cancer getting worse. About 600 participants will be random…

This early-stage trial tests a precise type of radiation (IMTMI) given with chemotherapy before a second donor stem cell transplant for people with advanced blood cancers that have returned. The goal is to find the safest dose and see if it can reduce side effects and prevent the…

This phase 2 trial is testing the drug daratumumab in 42 people with high-risk MGUS or low-risk smoldering multiple myeloma—early, pre-cancerous conditions that can lead to multiple myeloma. The goal is to see if daratumumab can produce a deep response (very good partial response…

This study tests a combination of four drugs (isatuximab, pomalidomide, elotuzumab, and dexamethasone) in people with multiple myeloma that has come back or stopped responding to at least two prior treatments. The goal is to see how well the drug combo controls the cancer. The st…

This Phase 2 trial tests whether adding daratumumab to a three-drug regimen (carfilzomib, lenalidomide, dexamethasone) works better than the three drugs alone for people newly diagnosed with multiple myeloma. About 310 participants will be randomly assigned to one of the treatmen…

This early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…

This study tests a new drug called Iberdomide (CC-220) alone or with other cancer drugs in people with multiple myeloma, a type of blood cancer. The trial has two parts: first, finding the safest dose, and second, seeing how well it shrinks tumors. About 466 participants are invo…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This phase 3 trial tests whether a new CAR-T cell therapy (cilta-cel) works better than the standard stem cell transplant for people newly diagnosed with multiple myeloma. About 759 participants will receive either CAR-T or a transplant after initial drug treatment. The main goal…

This study tests an oral enzyme called SYN-004 in adults who have received a stem cell transplant and need intravenous antibiotics for fever. The enzyme is designed to break down antibiotics in the gut, protecting the natural bacteria there. Researchers will check safety, whether…

This phase 2 trial tests whether using teclistamab or talquetamab (immune cell redirectors) after initial treatment can improve outcomes for newly diagnosed multiple myeloma. 103 patients receive either teclistamab with lenalidomide or teclistamab with talquetamab, depending on t…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This study tests whether giving patients with high-risk multiple myeloma specially engineered T-cells (CAR T-cells) after a stem cell transplant can safely improve outcomes. The T-cells are designed to target two proteins on myeloma cells, CD19 and BCMA. Researchers are monitorin…

This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This early-phase trial tests IBI363, a drug designed to both stimulate immune cells and block a cancer defense, in about 40 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goal is to find a safe dose and check for side effec…

This phase 2 trial tests daratumumab (Darzalex) combined with other drugs as a first treatment for multiple myeloma patients who are not eligible for a stem cell transplant. The goal is to see if this combination can achieve very good partial remission or better after 8 cycles, a…

This study follows about 100 people with multiple myeloma who previously received an experimental cell therapy called P-BCMA-101. Researchers will monitor them for up to 15 years to see how safe and effective the treatment remains over time. A safety switch drug called rimiducid …

This study tests whether adding two more drugs (carfilzomib and dexamethasone) to the standard maintenance drug lenalidomide after a stem-cell transplant can keep multiple myeloma from coming back longer. About 180 adults who have already had a transplant and are in stable condit…

This phase 3 trial tests whether a newer three-drug combination (carfilzomib, lenalidomide, dexamethasone, or KRd) works better than the current standard (bortezomib, lenalidomide, dexamethasone, or VRd) for people newly diagnosed with multiple myeloma. About 250 participants wil…

This early-phase trial tests a new treatment for multiple myeloma, a type of blood cancer. It uses a patient's own immune cells, modified to target a protein called BCMA on cancer cells, and may be combined with a drug called lenalidomide. The main goal is to find the safest dose…

This study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…

This phase 3 trial tests whether adding a CAR T-cell therapy (ide-cel) to standard lenalidomide maintenance can improve outcomes for adults with newly diagnosed multiple myeloma who had a poor response to stem cell transplant. About 79 participants will receive either the combina…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This phase 2 trial is testing a combination of four drugs—selinexor, bortezomib, dexamethasone, and daratumumab—in 62 patients with multiple myeloma that has returned or not responded to prior treatments. The goal is to see how many patients achieve a significant reduction in can…

This study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…

This study tests a combination of three drugs (bortezomib, lenalidomide, and dexamethasone) in people newly diagnosed with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see how well the drugs work together to control the disease. The trial incl…

This early-phase trial tests two drugs—venetoclax and tocilizumab—in people with a specific type of multiple myeloma (t(11;14)) that has come back or stopped responding to treatment. The study includes both African American and non-African American participants to see how safe th…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This early-phase study tests experimental cell therapies in 40 adults with relapsed and refractory multiple myeloma who have tried at least three prior treatments. The main goal is to check safety and find the right dose. While not a cure, it aims to control the disease and may l…

This early-stage trial tests a new therapy called SENTI-202, which uses specially designed immune cells (CAR NK cells) to find and attack cancer cells in people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The cells are 'off-the…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This phase 2 trial tests a new type of CAR-T cell therapy, called CART-ddBCMA, in 136 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The therapy uses a patient's own immune cells, modified to find and attack a protein cal…

This phase 3 trial tests whether adding daratumumab to a standard three-drug regimen (VRd) improves outcomes for people with newly diagnosed multiple myeloma who can undergo high-dose therapy. About 709 participants will receive either the four-drug combo or the standard three dr…

This phase 3 trial is testing whether adding the drug isatuximab to a standard combination of lenalidomide and dexamethasone, with or without bortezomib, can improve outcomes for newly diagnosed multiple myeloma patients aged 65 to 79 who are not eligible for a stem cell transpla…

This phase 2 study tests the drug selinexor combined with one of three other cancer drugs (carfilzomib, daratumumab, or pomalidomide) in 96 adults with multiple myeloma whose disease has worsened despite current treatment. Participants continue on the combination until the cancer…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This study tests a new treatment plan for people newly diagnosed with multiple myeloma, a type of blood cancer. The plan combines several drugs, including bortezomib and melphalan, with stem cell transplants and long-term maintenance therapy. The goal is to see if this approach w…

This study tests a new drug called TNB-383B in about 220 adults with multiple myeloma that has come back or not responded to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The main goals are to find the safest dose and check for …

This phase 3 trial tests whether adding the drug isatuximab to standard treatment helps people with newly diagnosed multiple myeloma achieve deeper remission and live longer without the cancer progressing. About 662 participants will receive either standard therapy or standard th…

This early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This study tests a new combination of three drugs (cyclophosphamide, abatacept, and tacrolimus) given at lower doses to prevent graft-versus-host disease (GVHD) in 27 adults receiving a stem cell transplant from a half-matched donor. GVHD is a serious condition where donor cells …

This study looked at 729 people with newly diagnosed multiple myeloma, aged up to 65. It compared a standard drug combination (lenalidomide, bortezomib, and dexamethasone) to the same drugs plus a stem cell transplant using the patient's own cells. The goal was to see if the tran…

This study tests a combination of two experimental drugs, talquetamab and teclistamab, in people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to find the safest and most effective dose and to see how well the drugs shrink tumors.…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This phase 3 trial tests whether adding BL-8040 to standard G-CSF helps collect more stem cells for transplant in multiple myeloma patients. About 180 participants received either the combo or a placebo. The goal is to see if more patients can collect enough cells in fewer sessio…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…

This early-phase trial tests a combination of three drugs—iberdomide (a pill), elotuzumab (given by IV), and dexamethasone—in people whose multiple myeloma has returned or stopped responding to prior treatments. The study is small (up to 37 people) and primarily looks at safety a…

This study tests a drug combination (isatuximab, carfilzomib, and dexamethasone) given under the skin to adults whose multiple myeloma has returned or stopped responding to prior treatments. The main goal is to see how well the cancer responds and to compare two ways of giving th…

This was a Phase 1 study designed to see how the drug belantamab mafodotin behaves in people with multiple myeloma who also have liver impairment. The goal was to check safety and drug levels in the blood. However, the study was withdrawn before any participants were enrolled, so…

This early-stage study tests a new drug, belantamab mafodotin, combined with standard treatments (bortezomib, lenalidomide, dexamethasone) in 118 adults newly diagnosed with multiple myeloma. The goal is to find the safest dose and schedule while monitoring side effects. Particip…

This study tests a new type of immune therapy for people with certain blood cancers (CLL, lymphoma, or multiple myeloma) that have come back or not responded to treatment. Researchers take a patient's own T cells, add a special receptor that targets a protein called kappa on canc…

This study tests whether improved nutritional support, delivered through digital tools and personalized advice, can reduce malnutrition in cancer patients. Around 130 adults with gynecologic, colorectal, or lymphoma cancers will receive either standard dietary advice or enhanced …

This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…

This study is testing a blood screening program to find multiple myeloma and its early stages (MGUS and smoldering myeloma) in Black adults aged 50 and older. Participants get a simple blood test and fill out questionnaires about their experience and knowledge of the disease. Tho…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immun…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This trial evaluates a new device called PointCheck that aims to detect severe neutropenia—a dangerous drop in infection-fighting white blood cells—without needing a blood sample. The study includes about 210 people with diffuse large B-cell lymphoma or multiple myeloma who are r…

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This study looks at whether a new radioactive tracer called PentixaFor can find multiple myeloma lesions more accurately than the standard FDG tracer during PET scans. About 45 adults with symptomatic multiple myeloma, either newly diagnosed or in relapse, will receive both types…

This study tests whether a single urine sample (spot urine) can detect myeloma proteins as accurately as the standard 24-hour urine collection. Researchers will compare results from 180 multiple myeloma patients starting a new treatment. If the spot test works well, it could make…

This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…

This early-stage trial tests whether the drug ruxolitinib can prevent chronic graft-versus-host disease (cGVHD) in 42 adults who had a stem cell transplant for blood cancer. Doctors use a blood test to find patients at high risk for cGVHD and then give them ruxolitinib to block t…

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

Researchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…

This study looks at how cancer patients feel about using marijuana products (THC or CBD) compared to opioids for pain relief. Researchers will survey 200 adults with cancer-related pain who are already taking strong opioids. The goal is to understand patient preferences and perce…

Researchers in Greece are testing a nine-session group program called TRANSFORM for people who have finished treatment for blood cancers such as leukemia, lymphoma, and myeloma. The program combines teaching, reflection, coping exercises, and mindfulness to see whether it can spa…

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…

This study tests a program called ASCENT that helps cancer survivors manage pain using an educational guide and coaching from community health workers and pain care managers. The goal is to improve pain control and lower the risk of opioid misuse. About 660 adults with cancer-rel…

This study tests whether inhaling lavender aromatherapy oil can reduce anxiety and pain for cancer patients undergoing a bone marrow biopsy. About 45 adults with cancer will be asked to use the oil during the procedure. The goal is to see if this simple, drug-free approach is som…

This pilot study explores whether chaplain-led compassion meditation can improve spiritual care for patients about to undergo stem cell transplantation for lymphoma or multiple myeloma. Half of the participants will receive these meditation sessions, while the other half gets sta…

This study tests a digital program called MINDSET designed to help newly diagnosed cancer patients cope better with treatment. 440 participants will use either the program or a control, and complete questionnaires and blood tests. The goal is to see if the program improves physic…

This phase III trial tests whether listening to music during a bone marrow biopsy or aspiration can lower anxiety. About 113 adults with blood cancers will be randomly assigned to either receive standard care or also listen to music during the procedure. Researchers will measure …

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study explores whether an online expressive writing workshop can boost mental wellness in young adults (ages 18-39) with blood cancer. One hundred participants will either start the workshop right away or wait four weeks. Everyone takes surveys about their mood and stress ov…

This study tests if fast-acting opioids (fentanyl or morphine) can reduce shortness of breath during or after walking in 150 cancer patients who already take strong painkillers. Participants will take the drug or a placebo before a short walk test, and researchers will measure ch…

This study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…

This trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…

This study tests whether using virtual reality (VR) can improve symptoms like pain, anxiety, and fatigue in patients receiving a bone marrow transplant. About 28 adults will be randomly assigned to either VR sessions or standard care during their hospital stay. The goal is to see…

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tests whether a virtual reality (VR) program can help people undergoing bone marrow transplants cope with stress and improve their quality of life. About 80 adult patients with blood cancer will be randomly assigned to either receive the VR program plus usual care, or …

This study tests a mobile app called THRIVE-M designed to help people with multiple myeloma cope with symptoms, emotions, and relationships. About 120 patients will either use the app or receive usual care. Researchers will measure whether the app improves quality of life, reduce…

This study tests whether a brief behavioral therapy (BBT-CI) or a healthy eating education program (HEAL) works better for reducing insomnia in cancer patients. About 400 adults with stage I-IV cancer who are currently receiving treatment and have sleep problems will take part. T…

This study tests whether a structured exercise program can reduce chemotherapy-induced peripheral neuropathy (CIPN) — nerve damage causing pain, numbness, or tingling. About 133 cancer patients who received certain chemotherapies will either follow an exercise plan or receive sta…

This study tests whether a relaxation breathing exercise can help reduce nausea and vomiting caused by chemotherapy in people with blood cancers. Sixty-eight patients are split into two groups: one does breathing exercises three times a day plus standard care, the other gets stan…

This pilot study tests whether aromatherapy inhaler sticks can reduce nausea and vomiting in 30 patients receiving chemotherapy as part of a stem cell transplant. Participants use the inhaler every four hours and whenever they feel sick. Half get essential oils, half get a placeb…

This study follows 72 adults with multiple myeloma who switch from a bortezomib- or carfilzomib-based treatment to an ixazomib-based regimen. Researchers are tracking side effects and how long patients go without the disease getting worse. The goal is to see if this switch is a g…

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

Older adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

Researchers at Peking University First Hospital are studying how the immune system responds to SARS-CoV-2 infection in people who have blood cancers compared with people who have no underlying diseases. The observational study enrolls 60 participants and collects clinical details…

This study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…

This study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This early-stage trial is testing a new drug called RO7875913 in 40 healthy volunteers to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo. The study aims to find the right dose for future trials, but offers no direct treatme…

This study tests an expanded web-based decision aid for people with cholangiocarcinoma, colorectal cancer, or multiple myeloma. Participants use the tool to choose which genomic results—such as cancer biomarkers or inherited risks—they want to receive. The goal is to see if the t…

This study does not provide any new treatment. It follows about 1,000 adults who previously received CAR T-cell gene therapy at the NIH. Researchers will check for long-term side effects through blood tests, clinic visits, and annual phone calls for up to 15 years, as required by…

This study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study is investigating how common muscle loss, known as sarcopenia, is in people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will measure body composition using DXA scans and track hospital stays, disease progression, and survival. The goal is to see…

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study uses bone marrow samples from 70 people with blood cancers to create 3D organoids—tiny lab-grown models that mimic the tumor's environment. Researchers will test different chemotherapy combinations on these organoids to see which kills the most cancer cells. The goal i…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study will observe 30 adults in Taiwan with relapsed or refractory multiple myeloma who are taking elranatamab as part of their regular care. Researchers will track how quickly the cancer responds, how long the response lasts, and overall survival. The goal is to understand …

This study looks at how spirituality — personal beliefs, values, and meaning — influences adults recently diagnosed with blood cancers like lymphoma or leukemia, as well as their loved ones. Participants fill out three questionnaires about spiritual well-being, quality of life, a…

This study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …

This pilot study aimed to see if giving a logbook to patients hospitalized for a stem cell transplant could help reduce feelings of isolation and psychological stress. The study was withdrawn before enrolling any participants, so no results are available. It was planned at the Un…

This study planned to check how often the adrenal glands stop working properly after chemotherapy in adults with blood cancers. It aimed to measure cortisol levels after a stimulation test. However, the study was withdrawn before any participants were enrolled, so no results are …

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study looks at how doctors and patients feel about a new approach to picking antibiotics for people with blood cancers who have a reported penicillin allergy. The goal is to understand what might make it easier or harder to use this approach in everyday hospital care. About …

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This study observes 357 people with multiple myeloma to see how long it takes for the disease to come back after their first treatment. Participants visit their clinic every 3 months and receive standard care. The goal is to better understand relapse timing in real-life practice,…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study aims to find out how often cannabis withdrawal happens and how severe it is in patients with blood cancers who are hospitalized for a bone marrow transplant or CAR-T therapy. Researchers will track symptoms like mood changes and physical discomfort using a standard que…

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study looks at whether a test called MMprofiler can help doctors decide on the best treatment for people with multiple myeloma, a type of blood cancer. About 250 patients who are candidates for systemic treatment will have their tumor tested, and doctors will fill out questi…

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study tests whether personalized telehealth coaching can help young adult cancer survivors become more physically active and improve their diet. Researchers are enrolling 374 survivors aged 18-54 who are not very active. Participants receive one-on-one sessions with a clinic…

This study looks at whether training and support can help cancer clinics give special check-ups (called geriatric assessments) to patients aged 65 and older who are starting a new cancer treatment. These check-ups help find and address health issues, support needs, and daily life…

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…

This study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…

This study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study tests whether a program where older adults (65+) with blood cancer see a team of healthcare providers can help them stay fit and resilient after a stem cell transplant. The program includes health coaching, quality-of-life assessments, and questionnaires. The main goal…

This study looks at how different antibiotics change the friendly bacteria in the gut of people who have had a stem cell transplant and develop a fever with low white blood cells. The goal is to understand which antibiotics are gentler on these helpful bacteria, which may lead to…

This study collects information from 100 adults with breast, lung, gastrointestinal cancer, or multiple myeloma. Participants fill out weekly online surveys about their symptoms and treatment experiences for at least 12 weeks. The goal is to learn how symptoms change over time an…

This study uses artificial intelligence to analyze the shape of individual myeloma cells from bone marrow samples. The goal is to predict genetic abnormalities (called FISH abnormalities) without relying on subjective human review. If it works, this AI method could make genetic t…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study looks at a new method for giving the cancer drug vincristine to infants and young children. The goal is to see if this new way of calculating the dose leads to similar drug levels in the blood as the standard method used in older children. About 83 children up to 12 ye…

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study examines stored lymph node samples from 100 people in Botswana who had lymphoma between 2012 and 2017. Researchers want to see how often Epstein-Barr virus (EBV) is found in these samples, and whether HIV infection makes a difference. The goal is to better understand t…

This study looks at how photobiomodulation (a type of light therapy) affects mouth sores and other oral symptoms in patients receiving a stem cell transplant. Researchers will track pain, taste changes, and dry mouth in about 6 patients. The goal is to gather information to impro…

This observational study follows 75 people with relapsed or refractory multiple myeloma who are already taking selinexor combined with bortezomib and dexamethasone. Researchers will track quality of life, side effects, and how the treatment works in everyday medical practice. The…

This study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…

This study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…

This study is screening over 80,000 people in Iceland to see if early detection of a condition called MGUS can prevent or improve outcomes for multiple myeloma, a type of blood cancer. Participants are randomly assigned to routine care or closer monitoring. The goal is to compare…

This study is checking if two substances in the blood, called IGF-1 and IGF-1Ec, are linked to how much cancer is in the body. Researchers will measure these levels in 100 adults with solid tumors and compare them to tumor size, stage, and spread. The goal is to see if these mark…